PTCT 250117 46.00C (PTCT250117C46000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PTCT250117C46000

Watchlist

2.35
0.000.00%

15min DelayTrading Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $45
Moomoo NewsJan 21 23:33 ET · Ratings
PTC Therapeutics (PTCT) Receives a Hold From Leerink Partners
TipRanksJan 21 22:35 ET · Ratings
Express News | PTC Therapeutics Inc : Leerink Partners Cuts Target Price to $45 From $50
ReutersJan 20 10:58 ET
PTC to Announce Fiscal Q1'25 Results on Wednesday, February 5th, 2025
PR NewswireJan 15 09:49 ET
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $76
Moomoo NewsJan 15 08:31 ET · Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
TipRanksJan 15 08:18 ET · Ratings

Comments

Lnova

Dec 19, 2024 17:24

$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...

Meltyy

May 22, 2024 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20, 2024 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3, 2024 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14, 2024 08:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy